Intracellular lipid metabolism impairs β cell compensation during diet-induced obesity

Risheng Ye, …, Joachim Herz, Philipp E. Scherer


The compensatory proliferation of insulin-producing β cells is critical to maintaining glucose homeostasis at the early stage of type 2 diabetes. Failure of β cells to proliferate results in hyperglycemia and insulin dependence in patients. To understand the effect of the interplay between β cell compensation and lipid metabolism upon obesity and peripheral insulin resistance, we eliminated LDL receptor–related protein 1 (LRP1), a pleiotropic mediator of cholesterol, insulin, energy metabolism, and other cellular processes, in β cells. Upon high-fat diet exposure, LRP1 ablation significantly impaired insulin secretion and proliferation of β cells. The diminished insulin signaling was partly contributed to by the hypersensitivity to glucose-induced, Ca\(^{2+}\)-dependent activation of Erk and the mTORC1 effector p85 S6K1. Surprisingly, in LRP1-deficient islets, lipotoxic sphingolipids were mitigated by improved lipid metabolism, mediated at least in part by the master transcriptional regulator PPARγ2. Acute overexpression of PPARγ2 in β cells impaired insulin signaling and insulin secretion. Elimination of Apbb2, a functional regulator of LRP1 cytoplasmic domain, also impaired β cell function in a similar fashion. In summary, our results uncover the double-edged effects of intracellular lipid metabolism on β cell function and viability in obesity and type 2 diabetes and highlight LRP1 as an essential regulator of these processes.

Find the latest version:

http://jci.me/97702/pdf
Intracellular lipid metabolism impairs β cell compensation during diet-induced obesity

Risheng Ye,1,2 Ruth Gordillo,1 Mengle Shao,1 Toshiharu Onodera,1 Zhe Chen,1,3 Shiuhwei Chen,1 Xiaoli Lin,1 Jeffrey A. SoRelle,3 Xiaohong Li,1 Miao Tang,3 Mark P. Keller,3 Regina Kuliawat,1 Alan D. Attie,4 Rana K. Gupta,1 William L. Holland,1 Bruce Beutler,3 Joachim Herz,6,7 and Philipp E. Scherer1

1Touchstone Diabetes Center, Department of Internal Medicine, University of Texas Southwestern (UTSW) Medical Center, Dallas, Texas, USA. 2Department of Medical Education, Texas Tech University Health Sciences Center Paul L. Foster School of Medicine, El Paso, Texas, USA. 3Center for the Genetics of Host Defense, UTSW Medical Center, Dallas, Texas, USA. 4Department of Biochemistry, University of Wisconsin, Madison, Wisconsin, USA. 5Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, New York, New York, USA. 6Departments of Molecular Genetics, Neuroscience, Neurology and Neurotherapeutics, and Center for Translational Neurodegeneration Research, UTSW Medical Center, Dallas, Texas, USA. 7Center for Neuroscience, Department of Neuroanatomy, Albert Ludwig University, Freiburg, Germany.

The compensatory proliferation of insulin-producing β cells is critical to maintaining glucose homeostasis at the early stage of type 2 diabetes. Failure of β cells to proliferate results in hyperglycemia and insulin dependence in patients. To understand the effect of the interplay between β cell compensation and lipid metabolism upon obesity and peripheral insulin resistance, we eliminated LDL receptor–related protein 1 (LRP1), a pleiotropic mediator of cholesterol, insulin, energy metabolism, and other cellular processes, in β cells. Upon high-fat diet exposure, LRP1 ablation significantly impaired insulin secretion and proliferation of β cells. The diminished insulin signaling was partly contributed to by the hypersensitivity to glucose-induced, Ca2+-dependent activation of Erk and the mTORC1 effector p85 S6K1. Surprisingly, in LRP1-deficient islets, lipotoxic sphingolipids were mitigated by improved lipid metabolism, mediated at least in part by the master transcriptional regulator PPARγ2. Acute overexpression of PPARγ2 in β cells impaired insulin signaling and insulin secretion. Elimination of Apbb2, a functional regulator of LRP1 cytoplasmic domain, also impaired β cell function in a similar fashion. In summary, our results uncover the double-edged effects of intracellular lipid metabolism on β cell function and viability in obesity and type 2 diabetes and highlight LRP1 as an essential regulator of these processes.

Introduction

At early stages of type 2 diabetes, β cells increase insulin production by hyperplasia as a compensatory response to insulin resistance in peripheral tissues (1). At that stage, the systemic glucose homeostasis remains intact until, at later stages, β cell failure and frank diabetes ensue. Therefore, maintenance of adequate β cell volume and function is key to managing patients with impaired fasting glucose and/or glucose tolerance. Insulin signaling in β cells plays a major role in their volume and functional compensation to diet-induced obesity (DIO) and peripheral insulin resistance (1, 2). However, the regulatory mechanism or mechanisms by which β cell insulin signaling is homeostatically maintained remain unclear.

During DIO, the most prevalent cause of type 2 diabetes, β cell viability is challenged by glucolipotoxicity (3) through cytotoxic metabolites or signaling that results from high levels of glucose and fatty acids. Both of these classes of nutrients can ultimately be converted into ceramides, a class of lipotoxic sphingolipids that promote β cell apoptosis (4). We have previously shown that improvements in systemic (5) and intracellular (6) lipid metabolism reduce lipotoxicity and promote β cell regeneration in type 1 diabetes. Here, we set out to investigate the role of lipid metabolism in β cell function in the context of DIO and type 2 diabetes.

LDL receptor–related protein 1 (LRP1) is a member of the LDL receptor family (7, 8). As a transmembrane protein, LRP1 consists of multiple extracellular ligand-binding repeats and Ca2+-binding domains and binds to a variety of ligands, such as apolipoprotein E (apoE), α2M, and PDGFβ. Highly diverse functions of LRP1 have been reported in different tissues. For example, LRP1 is a major suppressor of aneurysm formation and atherosclerosis in vascular smooth muscle (9) and supports glucose and lipid metabolism in neurons (10, 11) and adipose tissue (12) as well as liver (13, 14). However, the mechanistic role or roles and impact on cellular physiology of LRP1 receptors in β cells have not been addressed.

In this study, we wanted to define LRP1 as a potential modulator of lipid metabolism in β cells. In B6:BTBR F2h/k mice, islet Lrp1 mRNA levels correlate negatively with fasting plasma insulin, glucose, and triglycerides. However, when we knocked out LRP1 specifically in mature β cells, the mice exhibited surprising decreases in β cell volume and glucose-stimulated insulin secretion (GSIS) during DIO. LRP1-deficient β cells are less proliferative and show lower insulin production, with impaired insulin signaling. They are hypersensitive to glucose-induced, Ca2+-dependent activation of Erk and the mTORC1 effector p85 S6K1, which eventually leads...
to insulin receptor substrate 2 (IRS-2) reduction. More surprisingly, LRP1-KO β cells alleviate lipotoxicity by improvements in lipid metabolism, as evidenced by upregulation of lipid enzymes and the key transcription factor PPARγ2. Overexpression of PPARγ2 in β cells directly reveals that intracellular lipid metabolism impairs β cell insulin signaling and GSIS during DIO. Ablation of Apbb2, a functional modulator of the cytoplasmic domain of LRP1, also leads to β cell dysfunction and systemic glucose intolerance. Collectively, our findings suggest a mechanism of glucolipotoxicity in β cells, i.e., that the adaptive signaling pathways combating high glucose and lipids can contribute to the eventual β cell failure in type 2 diabetes, and highlight LRP1 as an essential modulator of such double-edged adaptations.

**Results**

*Islet Lrp1 expression correlates with diabetes-related phenotypes.* To determine whether LRP1 plays a role in β cell function and glucose metabolism, we analyzed islet Lrp1 transcript abundance in a large population of genetically obese (Leptinob/ob) B6:BTBR F2 mice (15). Islet Lrp1 correlates positively with plasma glucose (R = 0.413, P = 1.2 × 10^{-21}, Figure 1A) and triglyceride (R = 0.381, P = 2.0 × 10^{-16}, Figure 1B) and negatively with plasma insulin (R = −0.581, P = 4.4 × 10^{-45}, Figure 1C). These results demonstrate that the genetic regulation of islet LRP1 is associated with a dysregulation of glucose homeostasis. However, the scatter in the population was significant. To probe for the relative contribution of LRP1 to the cellular homeostasis and responsiveness to glucose more directly, we decided to use a genetic approach to manipulate islet LRP1 levels and determine whether this association reflects a direct causal relationship between LRP1 and islet function.

*LRP1 is required for compensatory β cell hyperplasia and glucose metabolism in HFD-fed mice.* To directly investigate the physiological role of LRP1 in the insulin-producing β cell, we generated Lrp1-βKO, a mouse model allowing doxycycline-inducible (Tet-On), β cell-specific elimination of the Lrp1 gene (Figure 2A). In the Lrp1-βKO mice, homozygous Lrp1 floxed alleles (Lrp1^ff) (16) were crossed with the transgenes reverse tetracycline transactivator (rtTA) (17) and TRE-Cre. Expression of the rtTA protein is driven by the mouse insulin promoter (MIP) and thus exclusively active in β cells. In the presence of doxycycline, the rtTA protein activates the tetracycline response element–controlled (TRE-controlled) promoter and thus the local expression of Cre recombinase, which irreversibly converts the Lrp1 floxed alleles into KO alleles (Lrp1^−/−) in all mature β cells. Littermates lacking the TRE-Cre transgene were employed as the control group. Both Lrp1-βKO and control mice were first fed a doxycycline-containing diet for 2 weeks and then switched to regular chow diet (RD) or high-fat diet (HFD) (Figure 2A). Compared with what occurred in the control mice, elimination of LRP1 was evident in the isolated pancreatic islets of Lrp1-βKO mice at both mRNA (Figure 2B) and protein levels (Figure 2C). LRP1 depletion in β cells was further confirmed by immunofluorescence (Supplemental Figure 1A; supplemental material available online with this article; https://doi.org/10.1172/JCI97702DS1).

Surprisingly, Lrp1-βKO mice on RD showed a trend toward glucose intolerance compared with controls (Figure 2D). After HFD, while the control mice still maintained relatively normal glucose tolerance, Lrp1-βKO mice were significantly ineffective with respect to glucose disposal. HFD-fed control mice showed the
for β cell proliferation under both RD and HFD regimens (Figure 3, A and B). And we observed reduced expression of cell-cycle regulators cyclin A2 and Mdm2, a mediator of p53 degradation (18) (Supplemental Figure 2A).

To further understand the role of LRP1 in β cell function, we examined the intracellular structure by electron microscopy (Figure 3, C and D) and found more immature secretory granules in Lrp1-KO β cells. This phenotype can be attributed, at least in part, to the reduced expression of the insulin 1 gene (Figure 3E). In isolated Lrp1-βKO islets, we also observed significant reduction in Tcf7l2 (19), Pdx1 (20), and Neurod1 (21) mRNAs, key transcription factors for insulin expression and β cell proliferation (Figure 3E). There was no significant change in the mRNAs of insulin processing (Supplemental Figure 2B) or endoplasmic reticulum (ER) stress-signaling genes (Supplemental Figure 2C), expected increase in GSIS, thereby supporting the maintenance of normal glucose metabolism (Figure 2E). However, the compensatory increase in β cell output was largely diminished in the absence of LRPI. The reduction in insulin was the primary cause of the glucose intolerance in HFD-fed Lrp1-βKO mice because they were even more insulin sensitive than the control group during an insulin tolerance test (Supplemental Figure 1B). Meanwhile the differences in body weight, fat mass, and lean mass were not significant between the 2 groups (Supplemental Figure 1C).

The defective insulin production in HFD-fed Lrp1-βKO mice was associated with a more than 50% decrease in β cell volume compared with controls (Supplemental Figure 1D, and Figure 2, F and G). Quantitation of individual islet size in these animals revealed that the Lrp1-βKO islets were less hyperplastic (Supplemental Figure 1E). BrdU incorporation suggested LRP1 is critical for β cell proliferation under both RD and HFD regimens (Figure 3, A and B). And we observed reduced expression of cell-cycle regulators cyclin A2 and Mdm2, a mediator of p53 degradation (18) (Supplemental Figure 2A).

To further understand the role of LRPI in β cell function, we examined the intracellular structure by electron microscopy (Figure 3, C and D) and found more immature secretory granules in Lrp1-KO β cells. This phenotype can be attributed, at least in part, to the reduced expression of the insulin 1 gene (Figure 3E). In isolated Lrp1-βKO islets, we also observed significant reduction in Tcf7l2 (19), Pdx1 (20), and Neurod1 (21) mRNAs, key transcription factors for insulin expression and β cell proliferation (Figure 3E). There was no significant change in the mRNAs of insulin processing (Supplemental Figure 2B) or endoplasmic reticulum (ER) stress-signaling genes (Supplemental Figure 2C),
in β cell volume and insulin production. However, insulin-signaling components, including IRβ, IRS-2, and phosphorylated Akt, were moderately diminished when LRP1 was absent. The dramatic reduction in IRβ was further confirmed by immunofluorescence (Figure 4, C and D). Therefore, LRP1 is required to mediate proper compensatory insulin signaling in β cells in response to HFD.

We wanted to understand how β cell insulin signaling is regulated by LRP1. In the context of obesity, the phosphorylated, active form of CREB is implicated as a key transcription activator linking glucose metabolism with cAMP amplification, thereby triggering the induction of IRS-2 and cell-cycle regulators in β cells (1). LRP1 ablation led to a reduction in CREB levels; however, this was only seen in RD-fed animals, not in the HFD-fed cohort (Supplemental Figure 3, E and F). CREB seems therefore an unlikely candidate to be responsible for the impaired insulin signaling in the HFD setting.

The mTORC1 signaling pathway is activated by the insulin-Akt cascade and mediates cell growth (22). HFD did induce phosphorylation of the S6 kinase 1 (S6K1) p85 isoform, a direct downplaying the role of posttranslational regulation in insulin deficiency. In summary, these results demonstrate that LRP1 is required for the compensatory proliferation and insulin production of β cells upon HFD.

LRP1 regulates the insulin signaling pathway in β cells. We further investigated the insulin-signaling cascades in islets, since these pathways are well-established key regulators of β cell function and proliferation, especially for compensation to DIO and insulin resistance (2). While there is always plenty of insulin available locally, tonic insulin signaling is crucial for proper β cell functionality. At the mRNA level, we observed a significant reduction in IRS-1 and -2 as well as the glucose transporter Glut2 upon LRP1 ablation (Figure 4A). There was also a trend toward reduction (P = 0.06) in Gck expression, consistent with a defective insulin-signaling pathway in islets lacking LRPI. At the protein level, Lrp1-βKO islets from RD-fed mice showed a significant decrease in IRS-2 (Figure 4B and Supplemental Figure 3, A–D). HFD resulted in potent activation of insulin signaling in control islets, consistent with their compensatory upregulation in β cell volume and insulin production. However, insulin-signaling components, including IRβ, IRS-2, and phosphorylated Akt, were moderately diminished when LRP1 was absent. The dramatic reduction in IRβ was further confirmed by immunofluorescence (Figure 4, C and D). Therefore, LRP1 is required to mediate proper compensatory insulin signaling in β cells in response to HFD.

We wanted to understand how β cell insulin signaling is regulated by LRP1. In the context of obesity, the phosphorylated, active form of CREB is implicated as a key transcription activator linking glucose metabolism with cAMP amplification, thereby triggering the induction of IRS-2 and cell-cycle regulators in β cells (1). LRP1 ablation led to a reduction in CREB levels; however, this was only seen in RD-fed animals, not in the HFD-fed cohort (Supplemental Figure 3, E and F). CREB seems therefore an unlikely candidate to be responsible for the impaired insulin signaling in the HFD setting.
tor of mTORC1 activation, in control islets (Figure 5A), consistent with enhanced insulin signaling (Figure 4B and Supplemental Figure 3, A–D). However, to our surprise, Lrp1−βKO islets after HFD exhibited a paradoxical increase in p85 S6K1 phosphorylation (Figure 5A and Supplemental Figure 4, A–D). Such changes did not fully transmit to S6 phosphorylation (Figure 5A and Supplemental Figure 4E), which depends primarily on S6K2 or p70 S6K1 (23–25).

Instead, S6K1 activation can contribute, at least in part, to the suppression of IRS-2 as feedback inhibition (26) and, eventually, the failure of β cells to compensate (27, 28).

To explain the paradoxical induction of mTORC1 associated with reduced insulin signaling in Lrp1−βKO islets after HFD, we examined the activation of Erk, which may be an alternate activator of mTORC1, independent of Akt (29, 30). The levels of phosphorylated Erk were consistent with S6K1 phosphorylation in islets (Figure 5B and Supplemental Figure 4F). In vascular smooth muscle cells, LRP1 ablation led to dramatic induction of PDGFRβ and Erk activation (9). However, PDGFRβ induction was minor in Lrp1−βKO islets after HFD (Supplemental Figure 7, A and B). In cultured mouse islets, 15 minutes of high glucose treatment in the absence of exogenous insulin stimulated much higher phosphorylation of Erk in Lrp1−βKO than in control islets. This stimulation completely depended on the availability of extracellular Ca2+ (Figure 5C and Supplemental Figure 5). Consistent with the data in freshly isolated islets (Figure 5, A and B, and Supplemental Figure 4), phosphorylation of S6K1, but not S6, follows the changes of Erk activation. Interestingly, the reduction in IRS-2 protein levels was observed in Lrp1−βKO islets after high glucose treatment for 1 hour (Figure 5D and Supplemental Figure 6A), but not 15 minutes (Supplemental Figure 6, B–F), suggesting time-dependent, progressive signal transduction from phosphorylated S6K1 to IRS-2 suppression, which is supported by a previous in vitro study (26).

Taken together, our data suggest that after HFD, β cells require LRPI to suppress the glucose-stimulated, Ca2+-dependent over-activation of Erk and p85 S6K1, thereby avoiding the inhibitory response during HFD exposure on insulin signaling mediated by molecules such as IRS-2.

**Improved lipid metabolism in LRPI-deficient β cells.** LRPI deficiency disrupts lipid metabolism in multiple tissues (9–12, 14). So we aimed to determine whether this is also a contributing factor to the impaired β cell function and proliferation after HFD. Loss of LRPI has been shown to cause apoE accumulation in mouse embryonic fibroblasts (MEFs) and neurons (11) as well as reduced apoE-lipoprotein secretion from liver (14). However, apoE levels were similar between control and Lrp1−βKO islets after HFD (Supplemental Figure 7, A, C–E). Defective lipid metabolism leads to increased lipotoxicity in β cells, as indicated by the levels of ceramides, a group of sphingolipids (4). Surprisingly, we observed an overall decrease in ceramides in Lrp1−βKO islets (Figure 6A). The same trends also existed in the lipotoxic precursors and derivatives of ceramides, including dihydro- (Figure 6B), lactosyl- (Figure 6C), and hexosyl-ceramides (Figure 6D), but not in sphingomyelins (Supplemental Figure 8A), the major storage form of sphingolipids or sphingoid bases (Supplemental Figure 8B), the early precursors and catabolites of ceramides. The normal levels of sphingolipids or sphingoid bases (Supplemental Figure 8B), the early precursors and catabolites of ceramides. The normal levels of sphingolipids or sphingoid bases (Supplemental Figure 8B), the early precursors and catabolites of ceramides. The normal levels of sphingolipids or sphingoid bases (Supplemental Figure 8B), the early precursors and catabolites of ceramides. The normal levels of sphingolipids or sphingoid bases (Supplemental Figure 8B), the early precursors and catabolites of ceramides. The normal levels of sphingolipids or sphingoid bases (Supplemental Figure 8B), the early precursors and catabolites of ceramides. The normal levels of sphingolipids or sphingoid bases (Supplemental Figure 8B), the early precursors and catabolites of ceramides. The normal levels of sphingolipids or sphingoid bases (Supplemental Figure 8B), the early precursors and catabolites of ceramides. The normal levels of sphingolipids or sphingoid bases (Supplemental Figure 8B), the early precursors and catabolites of ceramides. The normal levels of sphingolipids or sphingoid bases (Supplemental Figure 8B), the early precursors and catabolites of ceramides. The normal levels of sphingolipids or sphingoid bases (Supplemental Figure 8B), the early precursors and catabolites of ceramides. The normal levels of sphingolipids or sphingoid bases (Supplemental Figure 8B), the early precursors and catabolites of ceramides. The normal levels of sphingolipids or sphingoid bases (Supplemental Figure 8B), the early precursors and catabolites of ceramides. The normal levels of sphingolipids or sphingoid bases (Supplemental Figure 8B), the early precursors and catabolites of ceramides. The normal levels of sphingolipids or sphingoid bases (Supplemental Figure 8B), the early precursors and catabolites of ceramides. The normal levels of sphingolipids or sphingoid bases (Supplemental Figure 8B), the early precursors and catabolites of ceramides. The normal levels of sphingolipids or sphingoid bases (Supplemental Figure 8B), the early precursors and catabolites of ceramides. The normal levels of sphingolipids or sphingoid bases (Supplemental Figure 8B), the early precursors and catabolites of ceramides. The normal levels of sphingolipids or sphingoid bases (Supplemental Figure 8B), the early precursors and catabolites of ceramides. The normal levels of sphingolipids or sphingoid bases (Supplemental Figure 8B), the early precursors and catabolites of ceramides. The normal levels of sphingolipids or sphingoid bases (Supplemental Figure 8B), the early precursors and catabolites of ceramides. The normal levels of sphingolipids or sphingoid bases (Supplemental Figure 8B), the early precursors and catabolites of ceramides. The normal levels of sphingolipids or sphingoid bases (Supplemental Figure 8B), the early precursors and catabolites of ceramides. The normal levels of sphingolipids or sphingoid bases (Supplemental Figure 8B), the early precursors and catabolites of ceramides. The normal levels of sphingolipids or sphingoid bases (Supplemental Figure 8B), the early precursors and catabolites of ceramides. The normal levels of sphingolipids or sphingoid bases (Supplemental Figure 8B), the early precursors and catabolites of ceramides. The normal levels of sphingolipids or sphingoid bases (Supplemental Figure 8B), the early precursors and catabolites of ceramides. The normal levels of sphingolipids or sphingoid bases (Supplemental Figure 8B), the early precursors and catabolites of ceramides. The normal levels of sphingolipids or sphingoid bases (Supplemental Figure 8B), the early precursors and catabolites of ceramides. The normal levels of sphingolipids or sphingoid bases (Supplemental Figure 8B), the early precursors and catabolites of ceramides. The normal levels of sphingolipids or sphingoid bases (Supplemental Figure 8B), the early precursors and catabolites of ceramides. The normal levels of sphingolipids or sphingoid bases (Supplemental Figure 8B), the early precursors and catabolites of ceramides. The normal levels of sphingolipids or sphingoid bases (Supplemental Figure 8B), the early precursors and catabolites of ceramides. The normal levels of sphingolipids or sphingoid bases (Supplemental Figure 8B), the early precursors and catabolites of ceramides. The normal levels of sphingolipids or sphingoid bas...
ceramides/lactosyl-ceramides/hexosyl-ceramides, are readouts of intracellular lipid metabolism (31). These data consistently indicate a mitigated level of lipotoxicity in Lrp1-βKO islets compared with control islets after HFD.

To understand how LRPI deficiency results in improved lipotoxicity in β cells after HFD, we examined the expression of lipid metabolism genes and detected a significant induction in lipid enzymes S1k27u2 (Figure 7A), Cyp2c29, Cyp2c67, Cyp2d9 (Figure 7B), and Scd1 (Figure 7C). As for transcriptional regulators, FoxO1 expression was significantly reduced (Figure 7D). More to the point, there was a 3-fold increase in the mRNA of PPARγ but not the total PPARγ expression was significantly reduced (Figure 7D). As a result, the mRNA of PPARγ1 was induced in control islets by HFD and was further increased upon LRPI ablation (Figure 7E–G). In contrast, RD-fed Lrp1-βKO mice displayed lower PPARγ levels in islets compared with controls, suggesting a different relationship between LRPI and PPARγ under normal conditions relative to the DIO setting. These results suggest that the induction of PPARγ2 may contribute, at least in part, to properly managing the lipid metabolism program in Lrp1-βKO islets after HFD.

Acute overexpression of PPARγ2 impairs β cell function and insulin signaling. To directly explore the role of intracellular lipid metabolism in β cell function, we generated Pparγ2-OE, a mouse model enabling doxycycline-inducible, β cell–specific expression of a FLAG-tagged mouse PPARγ2 protein (Figure 8A). Pparγ2-βOE (MIP-rtTA; TRE-Pparγ2) mice and their control littermates (MIP-rtTA) were fed on HFD for 4 months and then switched to doxycycline-containing HFD for 2 weeks. Both genotypes continued weight gain during these 2 weeks (Supplemental Figure 9A). Strikingly, Pparγ2-βOE mice, but not control mice, developed significant glucose intolerance after doxycycline treatment (Figure 8B). While control mice exhibited an adaptive increase in GSIS, Pparγ2-βOE mice failed to do so (Figure 8C and Supplemental Figure 9B). Insulin–signaling proteins IRβ, IRS-2, and Akt and their phosphorylated forms were reduced in Pparγ2-βOE islets compared with controls (Figure 8D and Supplemental Figure 10). However, this acute induction of PPARγ2 was not sufficient to change β cell volume (Supplemental Figure 9C). Collectively, local overexpression of PPARγ2, the master transcriptional activator of lipid metabolism, simultaneously impairs β cell insulin signaling and function, which recapitulates the response to LRPI deficiency in the islet.

Elimination of Apbb2 impairs β cell GSIS and systemic glucose tolerance. To obtain further mechanistic insights into how LRPI regulates lipid metabolism and β cell function, we wanted to further probe for a functional role of the LRPI cytoplasmic domain, which directly interacts with multiple adaptor proteins and initiates cellular trafficking and signaling cascades (8). Apbb2 is a member of the amyloid β (A4) precursor protein-binding family, which tethers amyloid precursor protein (APP) to the cytoplasmic domain of LRPI (32, 33) to form potential scaffolds for protein complex assembly (34). We utilized a KO mouse model of Apbb2 and observed significant glucose intolerance even under RD feeding (Figure 9A), mimicking the Lrp1-βKO phenotype after HFD (Figure 2D). When the isolated pancreatic islets were perfused with variable glucose concentrations, the Apbb2−/− islets displayed blunted insulin secretion upon high glucose stimulation (Figure 9B). During the hyperglycemic clamp experiments, GSIS was intact in WTs, but almost abolished in Apbb2−/− mice (Figure 9C). Their defective glucose tolerance was also demonstrated by the higher circulating glucose levels (Figure 9D) and lower glucose infusion rate (Figure 9E) at the hyperglycemic stage. Interestingly, Apbb2−/− islets showed reduced mRNA (Supplemental Figure 11A), but normal protein (Supplemental Figure 11B) levels of LRPI, suggesting that function rather than the amount of LRPI protein is regulated by Apbb2 in β cell GSIS. Disruption of Apbb2 may abolish the capacity of LRPI to handle basal lipid flux and mimic its dysfunction upon HFD stress.

Discussion
As a member of the LDL receptor family, LRPI plays highly diverse physiological roles in different tissues. It has been implicated in multiple human diseases, such as atherosclerosis, Alzheimer’s disease, inflammation, and cancer (8). LRPI modulates TGF-β and PDGFβ signaling (9, 35, 36) and regulates cholesterol export in vascular smooth muscle cells (37). In neurons, LRPI supports insulin (38) and leptin (39) signaling, cellular glucose (40) and cholesterol uptake (11), and controls food intake. LRPI is also critical for lipid transport and metabolism in adipocytes (12, 41, 42). It improves the hepatic HDL/LDL secretion ratio (43) and protects hepatocytes from lipotoxic insults (44). Based on these reports in the literature, LRPI clearly performs unique functions in a cell type–specific way. It was, however, unclear what role LRPI exerts in the context of the β cell. Here, we
unravel the critical role of LRPI in β cell adaptation to DIO and insulin resistance. High levels of glucose and lipids stimulate Erk, S6K1, and PPARγ signaling to enable the β cells to manage the energy/nutrient surplus during DIO. As is the case for PDGFRβ and TGF-β signaling in smooth muscle cells, the crucial function of LRPI in islets is to moderate and prevent these signals from overactivation (Supplemental Figure 12A). In the absence of LRPI, the uncontrolled mTORC1 signaling and lipid metabolism programs both inhibit insulin signaling in the β cells and eventually lead to a reduction in insulin production (Supplemental Figure 12B). So the basal levels of LRPI act as an essential gatekeeper for β cells during DIO. Two recent studies demonstrated LRPI as a PPARγ coactivator in endothelial cells (45) and in macrophages (46). In contrast, in the context of the β cell, we show here that LRPI suppresses PPARγ. These findings further underline the tissue-specific functions of LRPI. Alternatively, LRPI may regulate PPARγ by spatially controlling its function. In the absence of LRPI, there could be a compensatory increase of PPARγ expression, which subsequently would deregulate other PPARγ2-dependent pathways in a maladaptive manner. In either case, there seems to be a close regulatory relationship between LRPI and PPARγ.

With nutrient surplus, activation of maladaptive pathways may be a new mechanism by which glucolipotoxicity exerts its negative effects in β cells. Previous studies showed in vitro that glucose activates Erk via an extracellular Ca2+ influx–dependent mechanism (47, 48). Erk can inhibit TSC2 and thus activate mTORC1 in parallel to Akt (25, 29). Activation of mTORC1 and S6K1 can inhibit insulin signaling in tissue culture or peripheral tissues (27, 49, 50), although the molecular mechanisms remain controversial (51). Degradation of IRS-2 proteins can be a key component (26), since IRS-2 is critical for β cell compensation to insulin resistance (52–57). For the first time, to our knowledge, our results link the axis of glucose/Ca2+/Erk/mTORC1/S6K1/Akt in β cells in vivo and demonstrate it as one of the mechanisms underlying the failed β cell compensation in type 2 diabetes.

Figure 6. Reduced lipotoxic sphingolipids in HFD Lrp1−βKO islets. Sphingolipids were assayed by mass spectrometry in pancreatic islets isolated from mice after doxycycline treatment and 8 months of HFD and normalized against the protein content of islet samples. n = 6 (control) and n = 4 (Lrp1−βKO) samples with 50 islets per sample. Sphingolipid species are categorized as (A) ceramides, (B) dihydro-ceramides, (C) lactosyl-ceramides, and (D) hexosyl-ceramides. The furthest left columns in every panel represent the sum of all species evaluated. Data are presented as mean ± SEM. *P < 0.05; **P < 0.01 for Lrp1−βKO versus control by 2-tailed unpaired Student’s t test. ND, not detected.
and insufficient PPAR\(\gamma\)2 in the presence of excessive LRP1 seem to be detrimental to \(\beta\) cell viability and function. Doxycycline-inducible deletion or overexpression mouse models will allow fine tuning of LRP1 levels in \(\beta\) cells and a more subtle dissection of the mechanistic changes. These experiments await future investigation.

The \(\beta\) cell requirement on LRP1 under HFD but not RD regimens provides mechanistic clues for LRP1 function. The damage control mechanisms of LRP1 upon glucolipotoxicity may not be needed or applicable when nutrient flux is normal. Another possibility is that LRP1 function is relevant, but redundant under RD. In contrast, Apbb2 KO results in defective GSIS in RD-fed mice, suggesting a fundamental role in \(\beta\) cell physiology. Apbb1, -2, and -3 are members of a group of proteins linking APP to the cytoplasmic domain of LRP1 (32, 33), and APP interacts with cholesterol metabolism in neurons (61). Ablation of Apbb2 may disrupt, not only the potential role of LRP1 in cholesterol metabolism, but also the molecular scaffolds containing LRP1 and APP, assembling protein complexes (34) and initiating pleiotropic intracellular signaling pathways. We speculate that targeted mutations of the LRP1 cytoplasmic domain will shed light on the molecular interactions critical for \(\beta\) cell function.

On the other hand, DIO leads to an induction of PPAR\(\gamma\)2, one of the master transcriptional activators of the lipid metabolism program in \(\beta\) cells. In addition to combating intracellular lipotoxicity, PPAR\(\gamma\)2 can impose inhibitory effects on \(\beta\) cell insulin signaling and GSIS. We demonstrate this directly with the \(\beta\) cell–specific overexpression mouse model. This can also provide more insights into the insulin-sparing effects of the thiazolidinediones (TZDs), which are PPAR\(\gamma\) agonists (58). Activation of PPAR\(\gamma\) in peripheral tissues, such as adipose tissue, can improve systemic lipid metabolism and insulin sensitivity through its beneficial effectors, e.g., adiponectin (5, 6). Meanwhile, TZDs will also activate PPAR\(\gamma\) in \(\beta\) cells and exert detrimental effects. These negative effects are at least partially suppressed by LRP1 action. Intriguingly, the complete ablation of PPAR\(\gamma\) or PPAR\(\gamma\)2 also prevents \(\beta\) cell volume expansion in obesity (59, 60). This may explain the negative correlation between islet LRP1 levels and plasma insulin in B6:BTBR F2\(\text{ob/ob}\) mice. Taken together, these findings suggest that both the level and activity of PPAR\(\gamma\)2 and its regulator LRP1 require tight control in \(\beta\) cells during obesity in order to maintain a favorable balance between lipid metabolism and insulin signaling that allows for \(\beta\) cell viability and adequate insulin production. Both excessive PPAR\(\gamma\)2 in the absence of LRP1 and insufficient PPAR\(\gamma\)2 in the presence of excessive LRP1 seem to be detrimental to \(\beta\) cell viability and function. Doxycycline-inducible deletion or overexpression mouse models will allow fine tuning of LRP1 levels in \(\beta\) cells and a more subtle dissection of the mechanistic changes. These experiments await future investigation.

The \(\beta\) cell requirement on LRP1 under HFD but not RD regimens provides mechanistic clues for LRP1 function. The damage control mechanisms of LRP1 upon glucolipotoxicity may not be needed or applicable when nutrient flux is normal. Another possibility is that LRP1 function is relevant, but redundant under RD. In contrast, Apbb2 KO results in defective GSIS in RD-fed mice, suggesting a fundamental role in \(\beta\) cell physiology. Apbb1, -2, and -3 are members of a group of proteins linking APP to the cytoplasmic domain of LRP1 (32, 33), and APP interacts with cholesterol metabolism in neurons (61). Ablation of Apbb2 may disrupt, not only the potential role of LRP1 in cholesterol metabolism, but also the molecular scaffolds containing LRP1 and APP, assembling protein complexes (34) and initiating pleiotropic intracellular signaling pathways. We speculate that targeted mutations of the LRP1 cytoplasmic domain will shed light on the molecular interactions critical for \(\beta\) cell function.

Figure 7. Improved lipid metabolism in HFD Lrp1-\(\text{jkO}\) islets. Experiments used pancreatic islets from mice 8 months after doxycycline treatment. (A–D) RT-qPCR of lipid metabolism genes in the HFD groups. \(n = 3\) to 4 mice per genotype. Data are presented as mean ± SEM. *\(P < 0.05\); **\(P < 0.01\) for Lrp1-\(\text{jkO}\) versus control by 2-tailed unpaired Student’s t test. (E–G) Representative Western blots (E) and quantitation (F and G) of both PPAR\(\gamma\) isoforms. \(n = 2\) mice per condition. Data are presented as mean ± SEM.
Methods

Mice. B6 and BTBR mice were intercrossed to generate the F2 cohort carrying the Leptin\textsuperscript{ob/ob} alleles by the Attie laboratory (62). The Lrp1 floxed (Lrp1\textsuperscript{fl/fl}) mouse strain was generated by the Herz laboratory (16). MIP-rtTA was generated by the Scherer laboratory (17, 63). TRE-Cre was purchased from the Jackson Laboratory (catalog 006234). TRE-Pparg2 was recently generated by the Gupta laboratory. The Apbb2-KO (Apbb2\textsuperscript{-/-}) mouse strain was generated by the Beutler laboratory using the CRISPR system. Female C57BL/6J mice were superovulated by injection with 6.5 U pregnant mare serum gonadotropin (PMSG) (Millipore), then 6.5 U human chorionic gonadotropin (hCG) (Sigma-Aldrich) 48 hours later. The superovulated mice were subsequently mated with C57BL/6J male mice overnight. The offspring were genotyped and transferred to RPMI 1640 medium with 10% FBS, 1% antibiotics, 5 mM glucose, 2 mM GlutaMAX-I (Gibco, Thermo Fisher Scientific, catalog 35050-061), and 0.2% BSA for overnight culture.

Islet isolation and culture. Mouse islets were isolated via collagenase digestion of exocrine pancreas as previously described (5). Freshly isolated islets were either snap-frozen with liquid nitrogen followed by -80°C storage for mRNA, protein, and sphingolipid analyses or pooled by genotypes and transferred to RPMI 1640 medium with 10% FBS, 1% antibiotics, 5 mM glucose, 2 mM GlutaMAX-I (Gibco, Thermo Fisher Scientific, catalog 35050-061), and 0.2% BSA for overnight culture. For signal transduction experiments, the overnight-cultured islets were first quiesced in secretion assay buffer (SAB) with specified supplements and incubated for 15 minutes or 1 hour. After incubation, islets were snap-frozen with liquid nitrogen and stored at -80°C for Western blotting.

RT-qPCR. The isolated islets were processed for reverse transcription (RT) and quantitative real-time PCR (qPCR) as described previously (6). Primer sequences are in Supplemental Table 1.
Western blotting. To prepare protein lysates, 1× SDS loading buffer (50 mM Tris-Cl, pH 6.8, 100 mM DTT, 2% SDS, 10% glycerol, 0.005% bromophenol blue) was added to the snap-frozen islets and incubated at 95°C for 10 minutes. As previously described (5), protein separation and transfer were performed with 4%-15% Mini-PROTEAN TGX Gels (Bio-Rad, catalog 456-1086), Trans-Blot Turbo Mini Nitrocellulose Transfer Packs (Bio-Rad, catalog 170-4158), and the Trans-Blot Turbo Transfer Starter System (Bio-Rad, catalog 170-4155). Primary antibodies included LRP1 (rabbit polyclonal 377, Herz laboratory) (65), β-actin (Novus, catalog NB600-501), IRβ (Santa Cruz Biotechnology Inc., catalog sc-711), IRS-2 (Upstate, catalog 06-506), pSer473-Akt (Cell Signaling Technology, catalog 9271), Akt (Cell Signaling Technology, catalog 9272), pSer133-CREB (Cell Signaling Technology, catalog 9272), pSer133-CREB (Cell Signaling Technology, catalog 9272), pThr202/Tyr204-Erk (Cell Signaling Technology, catalog 4370), Erk (Cell Signaling Technology, catalog 4695), PDGFRβ (Santa Cruz Biotechnology Inc., catalog sc-432), apoE (Santa Cruz Biotechnology Inc., catalog sc-6384), PPARγ (Cell Signaling Technology, catalog 2435), and GAPDH (Cell Signaling Technology, catalog 2118). Immunoblots were imaged on an Odyssey CLx infrared imaging system (LI-COR) and quantitated with ImageJ Gel Analyzer (NIH).

Immunohistochemistry. Mouse pancreata were harvested and processed for paraffin sections as previously described (5). For BrdU incorporation, mice were subjected to 3 consecutive daily i.p. injections of BrdU (100 μg/g BDW) before sacrifice. Primary antibodies used for immunostaining or immunofluorescence were as follows: insulin (Dako, catalog A0564), LRP1 (Herz laboratory), glucagon (Invitrogen, catalog 18-0064; Abcam, catalog ab10988), BrdU (AbD Serotec, catalog MCA2060), IRβ (Santa Cruz Biotechnology Inc., catalog sc-711), pThr389-S6K1 (Cell Signaling Technology, catalog 9206), and apoE (Santa Cruz Biotechnology Inc., catalog sc-6384).

Cell areas were quantitated by whole-slide scanning as previously described (5). Images were acquired on a Zeiss Axio Observer Z1 inverted microscope or an Olympus FSX100 all-in-one microscope. Fluorescence intensity and area were quantitated with ImageJ.

Figure 9. Apbb2 deletion impairs β cell function in RD-fed mice. Adult Apbb2-KO mice (Apbb2<sup>−/−</sup>) and WT littermates (Apbb2<sup>+/+</sup>) were fed on RD. (A) Blood glucose during i.p. glucose tolerance test (1 mg/g body weight). n = 6 (Apbb2<sup>−/−</sup>) and n = 9 (Apbb2<sup>+/+</sup>) mice. (B) Thirty islets per genotype were subjected to perifusion with glucose concentration at 2.7 mM (0–30 minutes), 16.7 mM (30–45 minutes), and 2.7 mM (45–55 minutes). Insulin concentrations of perifusion fractions were assayed and presented. (C–E) Plasma insulin (C), blood glucose (D), and glucose infusion rate (E) during hyperglycemic clamp. n = 3 mice per genotype. Data are presented as mean ± SEM. *P < 0.05; **P < 0.01 for Apbb2<sup>−/−</sup> versus Apbb2<sup>+/+</sup> mice by 2-tailed unpaired Student’s t test.
Glucose tolerance test. Mice were fasted for 4 to 6 hours and subjected to an oral gavage or i.p. injection of dextrose. Tail blood was collected at multiple time points and prepared for plasma. Glucose was assayed with a glucose meter or PGO enzymes (Sigma-Aldrich, catalog P7119) plus o-Dianisidine (Sigma-Aldrich, catalog F8803). Insulin was measured with ELISA kits (Crystal Chem, catalog 90080).

Transmission electron microscopy. Under isoflurane anesthesia, mice were subjected to cardiac perfusion of a perfusion buffer (4% paraformaldehyde, 1% glutaraldehyde, 0.1 M sodium cacodylate, pH 7.4). Pancreata were dissected, transferred to fixative (2.5% glutaraldehyde, 0.1 M sodium cacodylate, pH 7.4), minced to less than 1 mm pieces, and then processed at the UT Southwestern Microscopy Core Facility. Sections were examined with a JEOL 1200 EX electron microscope and photographed with a Sir Morada 11 MegaPixel side-mounted CCD camera.

Sphingolipid assays by mass spectrometry. Snap-frozen islets were assayed for sphingolipid species at the UT Southwestern Metabolic Phenotyping Core as previously described (8).

GSIS on perfused pancreata. Perfusions were performed as described (63). In brief, mouse pancreata were perfused with buffers containing either 2.7 mM glucose or 16.7 mM glucose (Sigma-Aldrich). All buffers before reaching the celiac artery were maintained at 37°C. Perfusates were then collected at 1-minute intervals for 25 minutes. Insulin levels were measured in perfusates using an insulin assay kit (Cisbio US Inc.).

Hyperglycemic clamp studies. Chronic indwelling catheters were aseptically placed in the right jugular vein, and hyperglycemic clamps were performed on conscious, unrestrained mice as we have previously described (6). Briefly, body weight-, and age-matched animals were fasted for 3 hours prior to a variable glucose infusion rate to increase and maintain blood glucose at approximately 260 mg/dl. Tail blood glucose was measured at 0, 3, 6, and 10 minutes and then every 5 minutes until 120 minutes. Blood samples to measure plasma insulin were taken at 0, 3, 6, 10, 15, 20, 30, 45, 60, 90, and 120 minutes.

Statistics. Kolmogorov-Smirnov test with Lilliefors correction was applied for data normality. Pearson product moment test was applied for correlation. Two-tailed Student’s t test was applied for all pairwise comparisons unless indicated. Statistical significance was defined as P < 0.05.

Study approval. All protocols for mouse use and euthanasia were reviewed and approved by the Institutional Animal Care and Use Committee of the UT Southwestern Medical Center and the University of Wisconsin Research Animal Resource Center.

Author contributions
RY designed and conducted experiments, acquired and analyzed data, and wrote the manuscript. RG conducted experiments and acquired and analyzed data. MS provided reagents and analyzed data. TO and ZC conducted experiments and acquired and analyzed data. SC and X Lin conducted experiments and acquired data. JAS, X Li, and MT conducted experiments and acquired and analyzed data. MPK conducted experiments and acquired and analyzed data. RK planned and conducted experiments and acquired and analyzed data. ADA designed experiments and analyzed data. RKG provided reagents and analyzed data. WHL designed and conducted experiments, acquired and analyzed data, and wrote the manuscript. BB designed experiments and analyzed data. JH provided reagents and analyzed data. PES conceptualized the studies, designed experiments, analyzed data, and wrote the manuscript.

Acknowledgments
We thank Xunde Xian and Yinyin Ding for helpful discussion. We thank the UT Southwestern Mouse Phenotyping Core for metabolic assays and mass spectrometry and the UT Southwestern Microscopy Core and Molecular Pathology Core for tissue embedding and processing. This study was supported by the NIH (grants R01-DK55758, R01-DK099110, and P01-DK088761-01 to PES; R01-DK101573 and R01-DK102948 to ADA) and the Juvenile Diabetes Research Foundation (JDRF 17-2012-36 to PES and 2-SRA-2016-149-Q-R to PES and WLH). PES was also supported by an unrestricted grant from the Novo Nordisk Research Foundation. RY was supported with a research fellowship from the Naomi Berrie Diabetes Center, Columbia University Medical Center. JH is supported by grants from the National Heart, Lung, and Blood Institute (NHBLI) (R37-HL63762), the National Institute of Neurological Disorders and Stroke (NINDS) (R01 NS09382), NINDS and the National Institute on Aging (NIA) (RF AG05391), the BrightFocus Foundation, and the Bluefield Project. JAS was supported by a Howard Hughes Medical Institute research fellowship.

Address correspondence to: Philipp E. Scherer, 5323 Harry Hines Boulevard, Dallas, Texas 75390-8549, USA. Phone: 214.648.8715; Email: philipp.scherer@utsouthwestern.edu.